Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4241 USD | -1.35% |
|
-3.28% | -69.92% |
Business Summary
Number of employees: 21
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medical Devices
60.7
%
| 3 | 54.4 % | 4 | 60.7 % | +8.55% |
Prescription Medications
39.3
%
| 3 | 45.6 % | 2 | 39.3 % | -16.39% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
77.7
%
| 5 | 80.1 % | 5 | 77.7 % | -5.68% |
International
22.3
%
| 1 | 19.9 % | 1 | 22.3 % | +8.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Shulman
CEO | Chief Executive Officer | 61 | - |
Fady Boctor
PSD | President | 47 | 01/20/01 |
Mitchell Arnold
AUD | Comptroller/Controller/Auditor | 61 | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Shulman
CEO | Chief Executive Officer | 61 | - |
Bruce Bernstein
BRD | Director/Board Member | 60 | 01/20/01 |
Joshua Silverman
BRD | Director/Board Member | 54 | 01/20/01 |
Wayne Walker
BRD | Director/Board Member | 65 | 01/20/01 |
Gregory Bradley
BRD | Director/Board Member | 64 | 01/20/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 7,000,195 | 6,189,085 ( 88.41 %) | 0 | 88.41 % |
Stock B | 0 | 5,663 | 0 | 0 |
Company contact information
Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas 3rd floor
10036, New York
+
http://www.petrospharma.com![address Petros Pharmaceuticals, Inc.(PTPI)](https://cdn.zonebourse.com/static/address/116081118.png)
Sector
Sales per Business
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.92% | 2.97M | |
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- PTPI Stock
- Company Petros Pharmaceuticals, Inc.